Related Experiment Video
Updated: Aug 8, 2026
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
Published on: January 3, 2017
Omega-3 treatment of childhood depression: a controlled, double-blind pilot study
Hanah Nemets1, Boris Nemets, Alan Apter
1Faculty of Health Sciences, Ben Gurion University of the Negev, Israel.
Insights
Omega-3 fatty acids show promise for treating major depressive disorder in children. This pilot study found significant improvements in depressive symptoms, suggesting a potential therapeutic benefit.
Area of Science:
- Pediatric Psychiatry
- Nutritional Neuroscience
Background:
- Childhood major depressive disorder (MDD) prevalence may be underestimated.
- Effective therapeutic options for pediatric MDD remain limited.
Purpose of the Study:
- To investigate the efficacy of omega-3 fatty acids as a monotherapy for major depressive disorder in children.
- To build upon previous findings of omega-3s in adult MDD.
Main Methods:
- A pilot study involving children aged 6-12 diagnosed with MDD.
- Randomized controlled trial comparing omega-3 fatty acids to placebo.
- Symptom assessment using Children's Depression Rating Scale (CDRS), Children's Depression Inventory (CDI), and Clinical Global Impression (CGI) at multiple time points.
Main Results:
- Analysis of variance revealed statistically significant positive effects of omega-3 fatty acid supplementation on depressive symptoms.
- Improvements were observed across all primary outcome measures: CDRS, CDI, and CGI.
Conclusions:
- Omega-3 fatty acids demonstrate potential therapeutic benefits for children with major depressive disorder.
- Further research is warranted to confirm these findings in larger pediatric populations.
Objective:
Major depressive disorder in children may be more common than previously thought, and its therapeutics are unclear. Because of success in a previous study on omega-3 fatty acids in adult major depressive disorder, the authors planned a pilot study of omega-3 fatty acids in childhood major depression.
Method:
Children who entered the study were between the ages of 6 and 12. Ratings were performed at baseline and at 2, 4, 8, 12, and 16 weeks using Children's Depression Rating Scale (CDRS), Children's Depression Inventory (CDI), and Clinical Global Impression (CGI). Children were randomized to omega-3 fatty acids or placebo as pharmacologic monotherapy. Twenty-eight patients were randomized, and 20 completed at least 1 month's ratings.
Results:
Analysis of variance showed highly significant effects of omega-3 on symptoms using the CDRS, CDI, and CGI.
Conclusions:
Omega-3 fatty acids may have therapeutic benefits in childhood depression.
